US8486941 — Phenyl amino pyrimidine compounds and uses thereof
Method of Use · Assigned to YM Biosciences Australia Pty Ltd · Expires 2030-01-03 · 4y remaining
What this patent protects
This patent protects phenyl amino pyrimidine compounds that inhibit JAK kinases, including JAK2 kinases, for use in treating various diseases.
USPTO Abstract
The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1201 |
— | momelotinib-dihydrochloride |
U-1201 |
— | momelotinib-dihydrochloride |
U-1201 |
— | momelotinib-dihydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.